小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析
Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma:its safety and efficacy analysis
张赛锋 1王道仁 2邵国良3
作者信息
- 1. 310053 浙江杭州 天台县人民医院(浙江省人民医院天台分院)放射科;浙江中医药大学研究生院
- 2. 310053 浙江杭州 天台县人民医院(浙江省人民医院天台分院)放射科
- 3. 中国科学院大学附属肿瘤医院(浙江省肿瘤医院)介入科
- 折叠
摘要
肝细胞癌(HCC)是全球最常见恶性肿瘤之一,经导管动脉化疗栓塞术(TACE)是治疗中晚期HCC重要方法.目前药物洗脱微球TACE(DEB-TACE)广泛应用于HCC治疗,并研究开发出不同品牌、不同大小载药微球.临床应用中根据肿瘤大小、血供情况选择载药微球粒径大小,一般推荐粒径为＜300 μm,目前较多选择粒径为100～300 μm,更小粒径载药微球近年开始应用.该文就小粒径载药微球(＜150 μm)有效性和安全性进行综述,以期为临床治疗提供参考.
Abstract
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors worldwide.Transarterial chemoembolization(TACE)has been an important method for the treatment of advanced HCC.At present,drug-eluting beads chemoembolization(DEB-TACE)has been widely employed in the treatment of HCC,and different brands and different sized drug-eluting beads have been developed and used in DEB-TACE.In clinical practice,the particle size of drug-eluting beads is selected according to the HCC size and its blood supply,generally,＜300 μm drug-eluting beads are recommended.At present,100-300 μm drug-eluting beads have been frequently used.In recent years,smaller-sized drug-eluting beads have been employed in TACE.This article reviews the clinical effectiveness and safety of small-sized drug-eluting beads(＜150 μm)in DEB-TACE for HCC,so as to provide reference for clinical treatment.
关键词
肝细胞癌/载药微球/经导管动脉化疗栓塞术Key words
hepatocellular carcinoma/drug-eluting bead/transcatheter arterial chemoembolization引用本文复制引用
出版年
2024
NETL
NSTL
万方数据